COMMUNIQUÉS West-GlobeNewswire

MDxhealth Enters into Distribution Agreement with Unilabs for SelectMDx for Prostate Cancer

30/10/2017 - 07:00

NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, October 30, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced that the company has entered into an agency [...]

MDxHealth a conclu un contrat de distribution avec Unilabs pour le test de détection du cancer de la prostate SelectMDx

30/10/2017 - 07:00

COMMUNIQUÉ DE PRESSE / INFORMATION REGLEMENTAIRE / INFORMATION PRIVILEGIEE IRVINE, CA, et HERSTAL, BELGIQUE - 07:00 CEST, 30 octobre 2017 - MDxHealth SA (Euronext : MDXH.BR) a annoncé aujourd'hui que l'entreprise avait [...]

argenx launches Phase I trial with subcutaneous formulation of ARGX-113

30/10/2017 - 07:00

Subcutaneous formulation intended for chronic therapy setting October 30, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep [...]

CapsoVision annonce l'obtention du marquage CE pour l'utilisation de sa vidéo-capsule CapsoCam Plus chez les patients âgés de 2 ans et plus

30/10/2017 - 07:00

La technologie disruptive de CapsoCam Plus offre des images latérales panoramiques de 360º et leur enregistrement dans la capsule, éliminant ainsi le recours à des équipements externes. SARATOGA, Californie, le 25 [...]

Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio

30/10/2017 - 07:00

Novartis to acquire Advanced Accelerator Applications pending outcome of tender offer and works council consultation Acquisition would add Lutathera ® , a first-in-class RadioLigand Therapy (RLT) approved in Europe and [...]

Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a

28/10/2017 - 08:55

PARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs. those on interferon beta-1a Currently there are no specifically approved disease modifying therapies for children and [...]

ABLYNX CLOSES $200 MILLION INITIAL PUBLIC OFFERING IN THE UNITED STATES

27/10/2017 - 22:30

REGULATED INFORMATION GHENT, Belgium, 27 October 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] , a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody® platform to develop treatments [...]

uniQure Announces Closing of its Public Offering

27/10/2017 - 22:03

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 27, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical [...]

UPDATE -- CapsoVision, Inc. Announces CE Mark for the Use of CapsoCam Plus Capsule Endoscopy System in Patients Ages 2 and Above*

27/10/2017 - 22:02

Award-winning technology provides 360º imaging, eliminates need for receiver equipment during examination SARATOGA, Calif., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Today Silicon Valley-based CapsoVision, Inc. announced CE [...]

NEOVACS : RÉSULTATS SEMESTRIELS 2017 ET POINT SUR LES AVANCÉES OPÉRATIONNELLES

27/10/2017 - 17:45

COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE RÉSULTATS SEMESTRIELS 2017 ET POINT SUR LES AVANCÉES OPÉRATIONNELLES FIN DU RECRUTEMENT DES PATIENTS DANS L'ÉTUDE CLINIQUE DE PHASE IIb AVEC l'IFNalpha [...]

NEOVACS PROVIDES BUSINESS UPDATE AND ANNOUNCES HALF-YEAR 2017 FINANCIAL RESULTS

27/10/2017 - 17:45

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS PROVIDES BUSINESS UPDATE AND ANNOUNCES HALF-YEAR 2017 FINANCIAL RESULTS COMPLETED PATIENT ENROLLMENT IN PHASE IIb CLINICAL STUDY OF IFNalpha KINOID FOR TREATMENT OF [...]

Shire plc : 3rd Quarter Results

27/10/2017 - 13:00

Shire reports strong earnings growth in Q3 2017; reiterates full year guidance Product sales increased 7%, mainly driven by rapid growth in Immunology franchise Generated $1.1 billion operating cash flow; remain on- [...]

Preferred Dental Technologies Inc. ("Company") (CSE: PDT): Addresses the growing digital dentistry market

27/10/2017 - 11:30

Prototypes for EAS have been successfully created in multiple materials WINNIPEG, Manitoba, Oct. 27, 2017 (GLOBE NEWSWIRE) -- PDT's Evolutionary Accessory Series (EAS) is used to create custom dental abutments for the [...]

Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review

27/10/2017 - 07:15

Comprehensive data package demonstrates that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of safety, efficacy and quality Pegfilgrastim is a long-acting version of oncology medicine filgrastim [...]

Targovax ASA: Resolutions to increase the share capital in Targovax ASA in relation to exercise of employee options and settlement of restricted stock units

27/10/2017 - 07:00

The board of directors of Targovax ASA (the "Company") has on 27 October 2017, in accordance with the authorisations granted by the general meeting on 5 April 2017, resolved: - to increase the share capital of up to NOK [...]

Vistin Pharma ASA : Third quarter 2017 results - strong growth, capacity expansion on track

27/10/2017 - 07:00

Norwegian pharmaceutical company Vistin Pharma ASA (OSE: VISTIN) experienced strong growth in the third quarter of 2017, with a 20 per cent increase in revenue from its metformin business. With a strong financial [...]

ABLYNX ANNOUNCES FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES AND END OF STABILIZATION PERIOD

27/10/2017 - 07:00

REGULATED INFORMATION - INSIDE INFORMATION GHENT, Belgium, 27 October 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] , a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody® platform [...]

Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline

26/10/2017 - 22:01

Galapagos Q3 Results This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]

Composition of the Nomination Committee of Orion Corporation

26/10/2017 - 17:45

ORION CORPORATION STOCK EXCHANGE RELEASE 26 OCTOBER 2017 at 18.45 P.M. EEST Composition of the Nomination Committee of Orion Corporation The Board of Directors of Orion Corporation has elected the following persons to [...]